JP2006504645A - 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療 - Google Patents

立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療 Download PDF

Info

Publication number
JP2006504645A
JP2006504645A JP2004519701A JP2004519701A JP2006504645A JP 2006504645 A JP2006504645 A JP 2006504645A JP 2004519701 A JP2004519701 A JP 2004519701A JP 2004519701 A JP2004519701 A JP 2004519701A JP 2006504645 A JP2006504645 A JP 2006504645A
Authority
JP
Japan
Prior art keywords
hcv
antibody
protein
peptide
cbh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004519701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504645A5 (https=
Inventor
ケイ．エイチ．フーング スティーブン
ケック ズェンユン
Original Assignee
ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ filed Critical ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ
Publication of JP2006504645A publication Critical patent/JP2006504645A/ja
Publication of JP2006504645A5 publication Critical patent/JP2006504645A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2004519701A 2002-07-02 2003-06-27 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療 Pending JP2006504645A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/188,608 US20030180284A1 (en) 1998-11-05 2002-07-02 Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
PCT/US2003/020580 WO2004005316A2 (en) 2002-07-02 2003-06-27 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes

Publications (2)

Publication Number Publication Date
JP2006504645A true JP2006504645A (ja) 2006-02-09
JP2006504645A5 JP2006504645A5 (https=) 2006-08-17

Family

ID=30114012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004519701A Pending JP2006504645A (ja) 2002-07-02 2003-06-27 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療

Country Status (5)

Country Link
US (1) US20030180284A1 (https=)
EP (1) EP1572721A4 (https=)
JP (1) JP2006504645A (https=)
AU (1) AU2003247841A1 (https=)
WO (1) WO2004005316A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014216A1 (ja) 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
JP2010518854A (ja) * 2007-02-21 2010-06-03 ユニバーシティー オブ マサチューセッツ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
WO2011052735A1 (ja) 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
ATE425187T1 (de) 2001-01-12 2009-03-15 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
EP2004684A4 (en) * 2006-03-22 2009-05-06 Genimmune N V THE HEPATITIS C-VIRUS NEUTRALIZING ANTIBODIES
WO2010047829A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Mutant hepatitis c virus e2 polypeptides for hcv treatment
WO2015141826A1 (ja) * 2014-03-20 2015-09-24 国立感染症研究所長が代表する日本国 Ｃ型肝炎ウイルスに対する感染阻害活性を有する抗体
CN106749645B (zh) * 2016-11-14 2019-12-03 广州泰诺迪生物科技有限公司 一种全人源抗丙型肝炎病毒的中和抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111858A1 (en) * 1991-07-15 1993-02-04 James S. Crowe Production of antibodies
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
BR9506059A (pt) * 1994-07-29 1997-10-28 Innogenetics Nv Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico
IL118626A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
AU2001292667A1 (en) * 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518854A (ja) * 2007-02-21 2010-06-03 ユニバーシティー オブ マサチューセッツ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
US8551484B2 (en) 2007-02-21 2013-10-08 University Of Massachusetts Human antibodies against hepatitis C virus (HCV) and uses thereof
WO2009014216A1 (ja) 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
WO2011052735A1 (ja) 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途

Also Published As

Publication number Publication date
US20030180284A1 (en) 2003-09-25
WO2004005316A2 (en) 2004-01-15
EP1572721A2 (en) 2005-09-14
EP1572721A4 (en) 2009-05-27
AU2003247841A1 (en) 2004-01-23
WO2004005316A3 (en) 2005-08-04
AU2003247841A8 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
US8114586B2 (en) Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US6692908B1 (en) Prevention and treatment of HCV infection employing antibodies that inhibit the interaction of HCV virions with their receptor
AU2022202819B2 (en) Antibody-mediated neutralization of Chikungunya virus
JP4105203B2 (ja) 診断用及び治療用の精製ｃ型肝炎ウイルスエンベロープ蛋白
KR101518081B1 (ko) Ｃ형 간염 바이러스(ｈｃｖ)에 대한 인간 항체 및 이것의 용도
CA2065287C (en) New hcv isolates
Burioni et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments
US8858947B2 (en) Hepatitis C antibodies and uses thereof
JPH0581600B1 (https=)
US7091324B2 (en) Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
JP2006504645A (ja) 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療
US6682909B2 (en) Immunogenic composition of hepatitis C and methods of use thereof
JP2000509966A (ja) Ｃ型肝炎ウイルス（ｈｃｖ）ｅ２抗原に特異的なヒトモノクローナル抗体
CA2412460C (en) Human monoclonal antibody against hepatitis c virus e2 glycoprotein
JP2004524829A (ja) Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用
Aghasadeghi et al. Evaluation of a native preparation of HCV core protein (2-122) for potential applications in immunization, diagnosis and mAb production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080624